Urinary Tract Infections Clinical Trial
Official title:
Prospective, Open-Label, Noncomparative, Multicenter Study to Evaluate the Efficacy and Safety of Ciprofloxacin Extended Release (Cipro XR) 1000 mg Tablets Given Once Daily for 7 to 14 Days in the Treatment of Patients 18 Years or Older With Complicated Urinary Tract Infections Caused by Pseudomonas Aeruginosa and Other Common Uropathogens
Researchers want to find out if a drug called Cipro® XR (ciprofloxacin extended-release) can help people with a complicated urinary tract infection caused by a kind of bacteria called Pseudomonas aeruginosa. The study doctor will give Cipro XR to some people to see if it is safe and works to treat complicated urinary tract infections caused by Pseudomonas aeruginosa. The study doctor will also gather information about using Cipro XR to treat complicated urinary tract infections caused by other bacteria. About 500 people with complicated urinary tract infections who are 18 years old and older will join this study. Cipro XR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections and acute uncomplicated pyelonephritis (inflammation of the kidney). The dose of Cipro XR used in this study (1000 mg a day for 7 to 14 days), has been shown to be safe and effective. This study is being done to gather more information on using this dose of Cipro XR for complicated urinary tract infections caused by Pseudomonas aeruginosa, as well as by other bacteria.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04495699 -
Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
|
||
| Terminated |
NCT05254808 -
EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
|
Phase 3 | |
| Completed |
NCT03680612 -
Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI
|
Phase 2 | |
| Completed |
NCT03282006 -
Treating Pyelonephritis an Urosepsis With Pivmecillinam
|
Phase 4 | |
| Completed |
NCT03526484 -
The Utility of Urinalysis Prior to In-Office Procedures
|
N/A | |
| Completed |
NCT05397782 -
Effects of Flourish on Recurrent Urinary Tract Infection
|
N/A | |
| Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
| Completed |
NCT03687255 -
Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
|
Phase 3 | |
| Recruiting |
NCT05227937 -
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
|
||
| Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
| Completed |
NCT03131609 -
Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
|
||
| Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
| Completed |
NCT01333254 -
A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients
|
N/A | |
| Terminated |
NCT00594594 -
Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury
|
Phase 1 | |
| Completed |
NCT00216853 -
A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection
|
N/A | |
| Completed |
NCT00787085 -
The Significance of Funguria in Hospitalized Patients
|
N/A | |
| Completed |
NCT05719753 -
The Effectiveness of a Bacteriophobic Coating on Urinary Catheters
|
N/A | |
| Recruiting |
NCT05415865 -
The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder
|
Phase 3 | |
| Not yet recruiting |
NCT05880329 -
DIagnoSing Care hOme UTI Study
|
||
| Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|